The melanocortin pipeline

How to read the ladder

Each bar shows the furthest stage an agent has reached, not where it is enrolling today, so a drug that has filed for approval still sits at Phase 3 until a regulator says yes. The same molecule can appear twice when it is being developed for two unrelated diseases, because the evidence for one does not transfer to the other. Discontinued programmes are kept rather than deleted: in this field the failures are as instructive as the approvals, and several of them explain why the current candidates are shaped the way they are.^[1]

What moved in 2026

This was the year the pipeline broadened beyond the three receptors it had lived on. Four things changed the map.

• Setmelanotide left rare genetics. In March the FDA extended setmelanotide to acquired hypothalamic obesity — weight gain after damage to the hypothalamus, typically from a craniopharyngioma or its surgery — on the strength of the Phase 3 TRANSCEND trial, in which treated patients lost 15.8% of BMI over a year against a 2.6% gain on placebo.^[3] It is the first approved therapy for the condition and the first time an MC4R agonist has been approved for an obesity that is not caused by a gene variant. The whole story is on the hypothalamic obesity page.
• An oral MC1R agonist reached the regulator. Dersimelagon, the first small-molecule MC1R agonist, met its primary endpoint in the Phase 3 INSPIRE trial in erythropoietic protoporphyria; its new drug application was accepted with priority review in 2026, with a decision expected in early 2027, and the programme changed hands from Tanabe to LEO Pharma.^[4]If approved it would be the first oral alternative to the afamelanotide implant.
• MC2R joined the pipeline. For thirty years the adrenal ACTH receptor was a diagnostic target and nothing more. Atumelnant, an oral MC2R antagonist, cut the androgen precursor androstenedione by up to roughly 80% in adults with congenital adrenal hyperplasia in a 12-week Phase 2 study,^[5] and in 2025–26 moved into a pivotal adult Phase 3 and a paediatric Phase 2/3.^[6] It is the first drug designed to turn a melanocortin receptor off at the adrenal, and the biology that makes it feasible is explained on the MC2R page.
• MC3R became a drug target in its own right. A 2026 primate study showed that an oral agonist activating both MC3R and MC4R cut body weight by 11.7% at 13 weeks in obese macaques, almost entirely as fat mass, and did more than a selective MC4R agonist alone.^[7] Dual MC3R/MC4R agonism is now the stated strategy of at least one company, and it moved the quieter appetite receptor from a footnote to a design goal — see MC3R.

Where each receptor stands

MC4R — agonists for obesity, antagonists for wasting. This is the busiest lane. On the agonist side, the question has shifted from whether MC4R activation causes weight loss, which setmelanotide settled, to whether it can be done in general obesity without raising blood pressure, and how it pairs with GLP-1 drugs. Every current obesity programme is positioned as a GLP-1 add-on: in Palatin's Phase 2 study, low-dose bremelanotide added to tirzepatide produced more weight loss than tirzepatide alone and stopped the rapid regain that followed withdrawing it.^[8] Rhythm's oral bivamelagon and weekly, MC1R-sparing RM-718 are both aimed first at hypothalamic obesity, with a Phase 3 of bivamelagon planned for late 2026,^[9] and Palatin's oral PL-7737 has entered Phase 1. The mechanics of why MC4R activation helps where GLP-1 leaves off are on the GLP-1 and appetite page. On the antagonist side, blocking MC4R lifts the brake on appetite, and mifomelatide (TCMCB07) is in Phase 2 for cancer cachexia; Pfizer's small-molecule PF-07258669 validated the same target before being shelved for business reasons.^[11]

MC1R — from protoporphyria outward. Afamelanotide opened the lane in 2019, and it is now in a fully enrolled Phase 3 in vitiligo, combined with narrow-band UVB phototherapy, with results expected at the end of 2026.^[10] Dersimelagon brings the first oral MC1R agonist, and is also in Phase 2 for diffuse cutaneous systemic sclerosis, where the receptor's anti-inflammatory rather than pigmentary action is the point. Palatin's gut-restricted PL-8177 showed clinical remission in a third of ulcerative colitis patients in a small Phase 2 before the company paused it to seek a partner. The unsolved problem across the lane is the one this site maps on the MC1R selectivity page: no agonist yet separates pigmentation from the receptor's other effects.

MC2R — the new antagonist lane. Atumelnant is the only clinical agent, but it is in Phase 3 for congenital adrenal hyperplasia and in a Phase 1/2b for ACTH-dependent Cushing's syndrome. Because MC2R reads a stretch of ACTH that no other melanocortin carries, an antagonist can be selective in a way the rest of the family cannot — the one lane where the selectivity problem is solved by the biology.

MC3R — newly in play. No selective MC3R agent is in the clinic, but dual MC3R/MC4R agonism is preclinical with primate data, and MC3R antagonism is half of what mifomelatide does.^[7]

MC5R — nothing yet. The exocrine receptor is studied for acne and inflammation and has no clinical candidate. It is the only one of the five without a drug in development.

What has failed, and what it taught

The pipeline's history is longer than its ladder suggests, because MC4R agonists for general obesity were tried, and abandoned, well before setmelanotide. The defining event came in 2009, when Lilly's peptide agonist LY2112688 raised blood pressure and heart rate in overweight volunteers after a week of infusion — and did not do so in people with MC4R loss-of-function variants, which showed the effect ran through the receptor itself.^[2] The field drew the conclusion that activating MC4R stimulates sympathetic outflow, and the general-obesity programmes of that era were wound down.^[1] The route back ran through rare disease: setmelanotide was developed in people whose MC4R pathway was demonstrably broken, where the benefit was large and the blood-pressure signal did not appear. Each current obesity candidate is, in some way, an answer to 2009 — a different dose, a different receptor-sparing profile, or a different pharmacology altogether, such as the biased and small-molecule agonists now being characterised in the lab.^[12]

The other discontinuations are smaller lessons. Intranasal bremelanotide was halted over blood pressure before the subcutaneous reformulation became Vyleesi, and PF-07258669 was stopped at Phase 1 for portfolio reasons rather than safety — a reminder that a validated target and a well-made molecule can still be shelved. For why the side effects of melanocortin agonists are inseparable from the mechanism, see why melanocortin agonists make you queasy and tan.

What to watch next

• Dersimelagon's FDA decision, expected in early 2027 — the first oral MC1R agonist, and the first test of whether a small-molecule melanocortin drug can clear the regulator.^[4]
• Afamelanotide's vitiligo readout, expected at the end of 2026 — a second indication that would move an MC1R agonist from a rare disease into a common one.^[10]
• Atumelnant's Phase 3 in congenital adrenal hyperplasia — if it holds up, the first approved antagonist of any melanocortin receptor.^[6]
• Bivamelagon's Phase 3 start and RM-718's maturing Phase 2 data — whether an oral or weekly MC4R agonist can match setmelanotide without the skin-darkening.^[9]
• Whether any MC4R agonist advances into general obesity as a GLP-1 partner rather than a rare-disease drug — the question the 2009 blood-pressure result left open.^[1]